Skip to main content

Table 1 Patient and treatment characteristics

From: Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer

  SE Region MPACT (Gem/NabP-arm)
Total number 75 (100) 431 (100)
Gender
 Female 34 (45) 186 (43)
 Male 41 (55) 245 (57)
Age median(range) 66 (48–80) 62 (27–86)
Distribution
  < 65 29 (39) 254 (59)
  ≥ 65 46 (61) 177 (41)
Length cm median(range) 172 (150–192)  
Weight kg median(range) 72 (41–121)  
Body surface kg/m2 median(range) 1.88 (1.4–2.37)  
ECOG Performance status
 0 33 (44) 69 (16)
 1 36 (48) 328 (76)
 2 6 (8) 32 (7)
CA19–9 U/ml median(range) 593.5 (1–140,000) 2293 (1.9–6,159,230)
Tumour stage
 Locally advanced 22 (29) 0 (0)
 Metastasised 53 (71) 431 (100)
Number of metastases
 1 8 (15) 33 (8)
 2 6 (11) 202 (47)
 3 2 (4) 136 (32)
  > 3 37 (70) 60 (14)
Metastatic site
 Liver 36 (50) 365 (85)
 Lung 20 (28) 153 (35)
 Peritoneum 6 (8) 19 (4)
 Skeleton 2 (3)  
 Pleura 2 (3)  
 Adrenal gland 2 (3)  
 Muscle 1 (1)  
 Pericardium 1 (1)  
 Kidney 1 (1)  
 Intestinal mesenterium 1 (1)  
Previous chemotherapy
 Neoadjuvant 3 (4)
 Adjuvant 24 (32)
 Concomitant with radiation 0 (0) 23 (5)
Previous Radiotherapy 0 (0) 19 (4)
  1. Number (%) were not else stated. SE South Eastern Region of Sweden